Germany Pharma Research (17)
17 papers in the Germany Pharma topic, indexed by PF-Atlas from PubMed and global journals.
- Immunomodulatory Effects of Nintedanib on Human Blood Monocytes/Macrophages from Patients with Idiopathic Pulmonary Fibrosis · Biomolecules · 2026
- Nerandomilast mechanism of action: preferential phosphodiesterase 4B inhibition in the treatment of pulmonary fibrosis · Video Journal of Biomedicine · 2026
- Tolerability and Safety of Nintedanib and Immunosuppression in Autoimmune Inflammatory Myopathy-Associated Progressive Pulmonary Fibrosis · CHEST Pulmonary · 2026
- Nintedanib Induces Mesenchymal-to-Epithelial Transition and Reduces Subretinal Fibrosis Through Metabolic Reprogramming · International Journal of Molecular Sciences · 2025
- Changes in Lung Function and Mortality Risk in Patients With Idiopathic Pulmonary Fibrosis · CHEST · 2025
- Trajectories of Health-Related Quality of Life in Patients With Idiopathic Pulmonary Fibrosis · CHEST Pulmonary · 2025
- Mechanisms on How Matricellular Microenvironments Sustain Idiopathic Pulmonary Fibrosis · International Journal of Molecular Sciences · 2025
- Targeted Therapy for Interstitial Lung Disease and the Role of Nerandomilast · EMJ Respiratory · 2025
- Serologically assessed markers of fibroblast activity and risk assessment of pulmonary fibrosis following severe COVID-19 infection · European Clinical Respiratory Journal · 2025
- Continued Treatment with Nintedanib in Patients with Progressive Pulmonary Fibrosis: Data from INBUILD-ON · Lung · 2025
- The burden of cough in idiopathic pulmonary fibrosis and other interstitial lung diseases: a systematic evidence synthesis · Respiratory Research · 2024
- Using group based trajectory modeling for assessing medication adherence to nintedanib among idiopathic pulmonary fibrosis patients · BMC Pulmonary Medicine · 2023
- Protocol for long-term effect of pulmonary rehabilitation under nintedanib in idiopathic pulmonary fibrosis · ERJ Open Research · 2021
- Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme · Respiratory Research · 2020
- Inhalation: A means to explore and optimize nintedanib's pharmacokinetic/pharmacodynamic relationship · Pulmonary Pharmacology & Therapeutics · 2020
- Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium · PharmacoEconomics - Open · 2020
- Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data · Advances in Therapy · 2020
Medical disclaimer. Research listings are for information only and are not medical advice.